Dewpoint Therapeutics

The discovery of biomolecular #condensates was an astounding breakthrough. A revelation so profound, it completely transformed the understanding of cellular function and organization. Discover how Dewpoint is exploring the relationship between condensate biology and human disease to advance therapies for diseases previously thought undruggable. https://lnkd.in/expN2ZSR #DiscoverDewpoint #biotechnology

Great coverage in The Pharma Letter about a major milestone for Dewpoint – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for the treatment of Wnt-driven cancers. Read the article: https://lnkd.in/g5S33rWM.

Our next Kitchen Table Talk is 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟯𝟬, with invited speaker Dragomir Milovanovic, Principal Investigator - Molecular Neuroscience, German Center for Neurodegenerative Diseases. 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗗𝗲𝘄𝗽𝗼𝗶𝗻𝘁 𝗞𝗶𝘁𝗰𝗵𝗲𝗻 𝗧𝗮𝗯𝗹𝗲 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁 “𝗖𝗼𝗻𝗱𝗲𝗻𝘀𝗮𝘁𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗮𝘁 𝘁𝗵𝗲 𝘀𝘆𝗻𝗮𝗽𝘀𝗲”. 👉 Register for the talk here: https://lnkd.in/gyDfsy-6  #condensates #neuroscience

💎Today we announced another major milestone for Dewpoint Therapeutics – the nomination of DPTX3186 as the first condensate modulating (#cmod) development candidate, for the treatment of Wnt-driven cancers. 💧C-mods are a novel class of therapeutic agents designed to modify disease by targeting biomolecular #condensates. 🔬DPTX3186 c-mod inhibits the function of a historically ‘undruggable’ target – beta catenin.  🧬In preclinical models of Wnt-driven cancers, DPTX3186 demonstrates significant tumor growth inhibition, stasis and regression.  Read more about the program here: https://lnkd.in/g4Yi22Jz Learn more about the novel mechanism of action of the beta catenin-targeting c-mods here: https://lnkd.in/gj8jUw5r  

Way to go Richard Young! Insightful thoughts about different mechanisms to approach correcting defects in gene regulation, including through a condensate targeting approach.

https://lnkd.in/gn_qSMpv

https://lnkd.in/g7ATbtFP

📢 We are thrilled to announce a significant milestone in the Dewpoint - Bayer AG collaboration: licensing of the first condensate modulating asset (#cmod) by Bayer, to be developed into a therapy to help patients suffering from genetically defined dilated cardiomyopathy. Read more here: https://lnkd.in/dTfiKWGG 

Dewpoint scientists Jesse Lai (ALS Biology) and Violeta Yu (Head of US Biology) had the great pleasure of attending the Society for Neuroscience 2024 meeting in Chicago, IL. During this exhilarating annual event, thousands of neuroscientists from around the world, including researchers, clinicians, and students collaborate, network, share cutting-edge discoveries, and discuss emerging trends. Jesse chaired the ALS Therapeutics session, as well as presented Dewpoint’s promising pre-clinical ALS TDP-43 condensate modulator (#cmod) program. Jesse’s presentation highlighted Dewpoint’s extensive use of iPSC-derived motor neurons and novel pre-clinical models to optimize a brain-penetrant small molecule therapy with the potential to treat >97% of patients. This well-attended session showcased the remarkable progress being made in both academia and industry towards delivering urgently needed effective treatments for patients. Thank you to the presenters and audience members for the lively discussions and inspirational progress!

Join Doug Baumann, Dewpoint Principal Scientist, at the 𝗥𝗲𝘃𝘃𝗶𝘁𝘆 𝗛𝗶𝗴𝗵 𝗖𝗼𝗻𝘁𝗲𝗻𝘁 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 on 𝗧𝘂𝗲𝘀𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟵 to learn about: ✅ Dewpoint’s AI-powered target and drug discovery platform ✅ Applications of condensate biology to modifying the function of historically ‘undruggable’ targets ✅ Dewpoint’s approach to condensate phenotype driven HTS to discover pioneering medicines Register for the symposium here: https://lnkd.in/gDya4DQH